Literature DB >> 12704346

IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy.

Bryce A Binstadt1, Raif S Geha, Francisco A Bonilla.   

Abstract

Polymorphisms of human Fc receptors (FcRs) have been described that are associated with the development or progression of autoimmune diseases. The FcR polymorphisms affect the affinity with which FcRs interact with immunoglobulin molecules. Intravenous immunoglobulin is administered as therapy for many autoimmune diseases and might exert its effects by interacting with FcRs. Thus, FcR polymorphisms might influence the efficacy of intravenous immunoglobulin therapy for patients with certain autoimmune diseases. In this article we review FcR polymorphisms in relation to autoimmune diseases for which intravenous immunoglobulin is used therapeutically.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704346     DOI: 10.1067/mai.2003.1380

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  16 in total

Review 1.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 2.  Functional and clinical consequences of Fc receptor polymorphic and copy number variants.

Authors:  S Bournazos; J M Woof; S P Hart; I Dransfield
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 3.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

4.  Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes.

Authors:  Doan C Nguyen; Franco Scinicariello; Roberta Attanasio
Journal:  Immunogenetics       Date:  2011-02-16       Impact factor: 2.846

Review 5.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

Review 6.  [B-cell-depleting antibodies in skin diseases].

Authors:  A Nagel; M Hertl; R Eming
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

7.  Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response.

Authors:  Sadeep Shrestha; Howard Wiener; Aditi Shendre; Richard A Kaslow; Jianming Wu; Aaron Olson; Neil E Bowles; Hitendra Patel; Jeffrey C Edberg; Michael A Portman
Journal:  Circ Cardiovasc Genet       Date:  2012-05-07

Review 8.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

9.  B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.

Authors:  Joseph M Tuscano; Jacob Sands
Journal:  Biologics       Date:  2009-07-13

10.  Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development.

Authors:  Masato Mitsuhashi; Mieko Ogura; Katsuya Endo; Kazuhiko Obara; Hiroshi Izutsu; Stephan R Targan; Motoko Maemura; Daisuke Tachikawa; Atsushi Shinagawa
Journal:  Pharm Res       Date:  2008-01-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.